Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture

Figure 4 Comparison of cumulative survival rates between surgery alone group and transarterial embolization/transarterial chemoembolization alone group. Cumulative survival rates in the surgery only or TAE/TACE only group (n = 20, median survival time of 8.32 mo; 95%CI: 6.93-9.57) and in the surgery or TAE/TACE plus sorafenib group (n = 12, median survival time of 16.41 mo; 95%CI: 10.97-21.83). Cumulative survival rates at 4, 8 and 12 mo were higher in the surgery or TAE/TACE plus sorafenib group (P = 0.04). TAE: Transarterial embolization; TACE: Transarterial chemoembolization.